Amorfix and Aragen Bioscience enter into agreement to develop novel monoclonal antibodies for the treatment of cancers
31-May-2010 -
Amorfix Life Sciences and Aragen Bioscience, Inc. announced that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several ...
apoptosis
Expression
monoclonal antibodies
+1